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1. Intoduction
Many pharmaceutical ingredients are not able to reach the 
market because of their poor solubility profile which inturn 
provides limited dissolution and gastrointestinal absorption 
(Shan & Zaworotko, 2008; Bhogala et al. 2005). The 
combination of pharmaceutical ingredient with coformers 
to form pharmaceutical adducts provides an opportunity to 
improve these physicochemical parameters (Yadav et al., 2009). 
These adducts are held together by hydrophobic interactions 
which do not alter the chemical properties of the active 
ingredient (Upadhyay et al., 2011; Friščić & Jones, 2010). 
These characteristics make pharmaceutical adducts a popular 
alternative to the traditional dissolution improving methods 
(Mirza et al., 2008; Babu & Nangia, 2011). Therefore, 
identification and characterization of pharmaceutical adducts 
plays a significant role in the field of pharmaceutical drug 
formulation development (Desiraju, 2010). 
Repaglinide (Rep), which is an oral hypoglycemic agent, 
belongs to BCS class 2 and the solubility of this molecule 
in water is found to be 0.0340 mg/ml indicating that it is 
practically insoluble in  aqueous medium. Repaglinide has 
two pKa values at 4.19 and 5.78, which makes it a weakly 
acidic compound, however the drug molecule is ionized at 
higher pH values. The present study has been designed to 
improve the solubility and dissolution rate of repaglinide 
and hence its oral absorption across the gastrointestinal tract 
by preparing multicomponent adducts.
Figure 1: Chemical structure of Repaglinide.
2. Experimental
2.1. Materials
Repaglinide was obtained as a gift sample from Aurbindo 
Pharma, Hyderabad India. HPMC, soluplus, sodium acetate, 
gallic acid, thiourea, benzoic acid, ascorbic acid and caffeine 
were procured from Himedia Laboratories, Mumbai, India. 
The methanol used in the study is of analytical grade.
Preparation of Cocrystal
The co-crystals are prepared by slow evaporation method 
containing drug to polymer ratio of 1:2 w/w respectively for 
all adducts i.e. B1, B2, B3, B4, B5, B6, B7, B8 (Table 1).
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1. Accurately weighed repaglinide in molar ratio and 
dissolved in 10ml methanol.
2. In a separate beaker co-former for different batches in 
molar ratio was taken and dissolved in 10 ml methanol.
3. Both the solutions were mixed properly and kept 
overnight for slow evaporation of solvent under fume 
chamber at room temperature.
4. The procedure was repeated with each co-former in 
triplicate.
5. The multicomponent adducts were collected and 
characterized to determine the optimum co-former for 
repaglinide adducts.
Table 1: Composition of different adducts.
Coding Drug Co-former REP: Co-
former (w/w)
B1 Rep Soluplus 1: 2
B2 Rep HPMC 1: 2
B3 Rep Sodium acetate 1: 2
B4 Rep Gallic acid 1: 2
B5 Rep Thiourea 1: 2
B6 Rep Benzoic acid 1: 2
B7 Rep Ascorbic acid 1: 2
B8 Rep Caffeine 1: 2
2.2. Characterization of Adducts
2.2.1. Percentage Yield
1. The obtained adducts were weighed accurately on 
analytical weighing balance and recorded.
2. The initial weight of components was calculated by 
adding the weight of repaglinide and co-former.
3. The percentage yield was calculated with the help of 
formula:
 % yield = weight of adducts/initial weight of 
components ×100.
2.2.2. Melting Point
1. Small amounts of drug, co-former and its adduct were 
filled in separate capillary tubes with one end sealed for 
determining the melting points.
2. The capillaries were inserted in melting point apparatus 
and the apparatus was turned on.
3. The temperature at which the drug, co-former and 
co-crystal melt was noted with the help of laboratory 
thermometer.
4. The procedure was repeated with all co-formers taken 
with their respective co-crystals and there melting point 
was noted.
2.2.3. Drug-Coformer Interaction
1. Accurately weighed 10 mg of adduct and dissolved in 
methanol to get a clear solution.
2. From this, 0.1 ml of solution was taken and transferred 
to a volumetric flask of 10 ml capacity and the volume 
was made upto mark with methanol.
3. From the above solution, again 1 ml of solution was 
taken and transferred to 5 ml volumetric flask and the 
final volume was made upto the mark.
4. The amount of drug entrapped was estimated with the 
help of UV spectrometer at 240 nm λmax.
2.2.4. Fourier Transform Infra-Red Spectroscopy
Fourier transform infra-red spectroscopy (FTIR) spectrum 
is characteristic property of a drug for its identification. It 
is used to identify the functional groups in the molecule. 
The drug was scanned at 4 mm/s at 2 cm-1 resolution over a 
wave number region of 400 to 4000 cm-1. The characteristic 
peaks at particular wave number were recorded and checked 
for characteristic functional groups present in molecular 
structure of the drug molecule.
2.2.5. Optical Microscopy
The microscopic study was done with the help of optical 
microscopy by Olympus. The sample was placed on glass 
slide and observed under microscope at 10x and the images 
were recorded.
2.2.6. Aqueous Solubility
1. Accurately weighed 10 mg of adduct and transferred to 
vials containing 1 ml distilled water.
2. The vials were kept in water bath shaker at room 
temperature for 24 hours.
3. Then, the vials were removed and the solution was 
centrifuged to settle down the undissolved material.
4. The supernatant was estimated for drug content with 
UV spectrometer at 240 nm λmax.
2.2.7. Dissolution Study
The dissolution profile of repaglinide and its adducts was 
obtained using USP XII apparatus (paddle type tribune). 
The medium consisted of 900 mL of buffer solution 
(phosphate buffer pH 7.4). The stirring speed was set at 
60 rpm. The media was already filtered, degassed and 
maintained at 37 ± 0.5 °C. The samples equivalent to 
10 mg of repaglinide were used. The samples of 5 ml 
were withdrawn after 15, 30, 60, 90, 120 and 240 min 
and analyzed till the absorbance of the solution attains a 
constant value.
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3. Results and Discussion
3.1. Preparation of Pharmaceutical Adducts by 
Slow Evaporation Technique
The adducts were prepared by slow evaporation technique 
containing drug to coformer ratio of 1:2 w/w respectively 
for all batches i.e. B1, B2, B3, B4, B5, B6, B7, B8 
(Table 2). However, the crystals of adducts were obtained 
only in B1 and B2 and no crystals were in batches B3- B8 
as can be seen in Table 2. The formation of any other form 
of product such as dispersions is ruled out as the both the 
components i.e. drug and coformers are taken in molar 
ratios.
Table 2: Product obtained in all the batches.









3.2. Characterization of Adducts
3.2.1. Percentage Yield
The percentage yield of obtained adducts is given in 
Table 3. It can be seen that there is high percentage yield 
of the product by slow evaporation method of preparation.
The percentage yield for both the batches i.e. B1 and 
B2 was found to be > 90% with the higher yield for B1 
i.e. 95.36 ± 0.12 %, which shows the greater ability of 
respective co-former (Soluplus) to prepare pharmaceutical 
adducts. There was no co-crystal formation for batch B3 to 
B8 which may be due to acidic nature of drug showing no 
bonding with acid group of coformers.
Table 3: Percentage yield of obtained adducts.
S. No. Batch % yield
1 B1 95.36 ± 0.12








The difference in range of capillary melting of repaglinide 
adducts suggested formation of new solid phases (Table 4). 
Further studies have been performed to confirm the existence 
of a new phase.
Table 4: Melting points of repaglinide and its adducts.







The drug entrapment for both the batches was found to be 
> 88 % with maximum entrapment of 96.03 ± 1.23 % for 
B1 (Soluplus) showing the ability of co-former to combine 
with required amount of drug (Table 5).
Table 5: Drug entrapment in repaglinde adducts.
S. No. Batch Drug entrapped ± SD
1 B1 94.19 ± 0.95
2 B2 92.98 ± 0.74
3.3.4. Fourier Transform Infra-Red Spectroscopy
Thespectra of  of adducts formed and repaglinide showed 
certain differences in the peak positions which are  shown 
in figures 2, 3 and 4. The most prominent peaks are at 
wavenumber 3305 cm-1 and 1685 cm-1 for –NH stretch 
and –C=O stretch respectively (Table 6). The variations 
in these two peaks is clearly evident in both the adducts as 
shown in Table 7 & 8. The range of wavelength in which 
this peak appears corresponds to the literature values for an 
alkyl stretch (C-H stretch) and C-O stretch respectively. It is 
evident that there is formation of bond between carboxylic 
moiety of repaglinide and hydrogen bond forming atom 
present in the coformers e.g. –OH of ascorbic acid, gallic 
acid and benzoic acid; –N of caffeine and thiourea; –CO 
of HPMC and soluplus. This suggests formation of new 
surfaces due to hydrogen bonding.
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Figure 2: FTIR spectrum of repaglinide.
Table 6: FTIR data of repaglinide.
S. No. Interpretation IR range Observed peak (cm-1)
1 N-H stretch 3200 - 3400 3305.72
2 C-H stretch 2850 - 3000 2937.17
3 C=O stretch 1680 - 1710 1685.96
4 C-O stretching 1180 - 1260 1212.80
Table 7: FTIR data of repaglinide-soluplus adduct.
S. No. Interpretation IR range Observed peak (cm-1)
1 N-H stretch 3200 - 3400 3416.96
2 C-H stretch 2850 - 3000 -
3 C=O stretch 1680 - 1710 16.8
4 C-O stretch 1180 - 1260 -
Figure 3: FTIR spectra of repaglinide-soluplus adducts.
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Figure 4: FTIR spectra of repaglinide-HPMC adducts.
Table 8: FTIR data of repaglinide-HPMC adduct.
S. No. Interpretation IR range 
cm-1
Observed peak (cm-1)
1 N-H stretch 3200 - 3400 3414.96
2 C-H stretch 2850 - 3000 -
3 C=O stretch 1680 - 1710 1637.8
4 C-O stretch 1180 - 1260 -
3.3.5. DSC Analysis
The DSC spectrum of repaglinide and its adducts is shown 
in Figure 5. It can be that the melting of repaglinde is 
observed at 126.8 °C. The DSC graph of adducts showed 
that the peak area and height decreased suggesting drug has 
interacted with the conformer resulting in the formation 
of a new phase  which has different melting point from 
repaglinide. 
3.3.6. Optical Microscopy
The optical microscopic images suggest the formation 
of crystalline structures in B2. The batch B2 shows the 
formation of needle shaped co-crystals while B1 (Soluplus) 
shows an amorphous type of structure suggesting greater 
solubility and ability of co-former to form co-crystals 
(Figure 6).
Figure 5: DSC thermogram of (a) Repaglinide (b) Rep-soluplus 
(c) Rep-HPMC.
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B1
B2
Figure 6: Optical microscopic images of various batches of adducts.
3.3.7. Aqueous Solubility
The solubility was found to increase in repaglinide in each 
batch. But, the batch B1 (Soluplus) shows greater increase 
in aqueous solubility of repaglinide showing the greater 
ability of this co-formers to increase the aqueous solubility 
of poorly water soluble drugs (Table 9).
Table 9: Aqueous solubility of repaglinide and its adducts.
S. No. Batch Solubility ± SD (%)
1 Rep 30.12 ± 0.38
2 B1 80.88 ± 0.53
3 B2 38.34 ± 1.25
3.3.8. Dissolution Study
The dissolution graph of repaglinide and the molecular 
adducts is shown in Figure 7. The dissolution profile suggests 
an increase of 1.1 and 2.25 times in the dissolution rate for 
molecular adducts with soluplus and HPMC respectively.
Figure 7: Dissolution profile of repaglinide and its adducts.
Conclusion
From the above study it can be concluded that poor solubility 
of pharmaceutical agents is a major limitation which can be 
overcome by preparing molecular adducts without affecting 
the chemical composition of the API. The pharmaceutical 
adducts formed in the present study showed better solubility 
and dissolution profile as compared to the pure repaglinide. 
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